Phase 2 Myeloma Trial, Recruiting (NCT06052826)

Phase 2 Myeloma Trial, Recruiting NCT06052826 Sponsor: City of Hope Medical Center Condition: Myeloma

Printed from Voxsanity (voxsanity.com.au) — NCT06052826 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Myeloma

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You must be able to give your agreement to take part in the study after being informed about it
Your own doctor must agree for you to take part
You must be able to read and complete surveys in English or Spanish (other languages may be accepted — confirm with trial site)
You must be aged 60 or older at the time you join the study
You must be scheduled to receive an FDA-approved CAR-T cell therapy to treat multiple myeloma or a type of blood cancer called B-cell non-Hodgkin lymphoma
You must be willing and able to complete all parts of the study as required
You must be able to attend at least one study visit before your pre-treatment chemotherapy (called lymphodepletion) begins

Who may not be able to join:

You have previously received CAR-T cell therapy
You have a health condition that the study doctor believes could make it unsafe for you to take part
The study doctor has concerns that you may not be able to follow through with all of the study steps and requirements (for example, due to practical or logistical reasons)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 26 July 2026

Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06052826

Sponsor: City of Hope Medical Center

Phase: Phase 2

Status: Recruiting

Condition: Myeloma

More information: https://clinicaltrials.gov/study/NCT06052826

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You must be able to give your agreement to take part in the study after being informed about it
Your own doctor must agree for you to take part
You must be able to read and complete surveys in English or Spanish (other languages may be accepted — confirm with trial site)
You must be aged 60 or older at the time you join the study
You must be scheduled to receive an FDA-approved CAR-T cell therapy to treat multiple myeloma or a type of blood cancer called B-cell non-Hodgkin lymphoma
You must be willing and able to complete all parts of the study as required
You must be able to attend at least one study visit before your pre-treatment chemotherapy (called lymphodepletion) begins

Who may not be able to join:

You have previously received CAR-T cell therapy
You have a health condition that the study doctor believes could make it unsafe for you to take part
The study doctor has concerns that you may not be able to follow through with all of the study steps and requirements (for example, due to practical or logistical reasons)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 26 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 2

Sponsor

City of Hope Medical Center

Registry

ClinicalTrials.gov

Start date

23 June 2023

Est. completion

5 October 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Changes in Short Physical Performance Battery (SPPB)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov